Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of TJ271 injection combined with pembrolizumab in Chinese patients with advanced solid tumors
CTR20220739Phase 2Unknown
- Sponsor
- I-Mab
- Start
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of enoblituzumab, pembrolizumab in non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC), melanoma, Nonhematologic neoplasms, sponsored by I-Mab. Status: unknown.
02
Drugs
enoblituzumabpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20220739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220739.